Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$10.54 - $18.14 $495,422 - $852,652
-47,004 Reduced 24.46%
145,174 $2.32 Million
Q1 2024

May 15, 2024

BUY
$6.63 - $17.3 $1.27 Million - $3.32 Million
192,178 New
192,178 $2.83 Million

Others Institutions Holding PEPG

About PepGen Inc.


  • Ticker PEPG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,631,900
  • Market Cap $85.8M
  • Description
  • PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...
More about PEPG
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.